Volume | 556,093 |
|
|||||
News | - | ||||||
Day High | 42.275 | Low High |
|||||
Day Low | 41.36 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Ionis Pharmaceuticals Inc | IONS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
41.75 | 41.36 | 42.275 | 41.59 | 41.84 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
10,225 | 556,093 | US$ 41.92 | US$ 23,310,620 | - | 34.32 - 54.4446 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
18:57:35 | 50 | US$ 40.34 | USD |
Ionis Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.06B | 145.75M | - | 787.65M | -366.29M | -2.51 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Ionis Pharmaceuticals News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IONS Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 40.88 | 42.725 | 40.385 | 41.57 | 806,586 | 0.71 | 1.74% |
1 Month | 43.31 | 44.08 | 40.385 | 42.20 | 896,329 | -1.72 | -3.97% |
3 Months | 50.31 | 51.98 | 40.385 | 44.39 | 1,094,081 | -8.72 | -17.33% |
6 Months | 44.59 | 54.4446 | 40.385 | 47.35 | 1,117,393 | -3.00 | -6.73% |
1 Year | 36.00 | 54.4446 | 34.32 | 44.40 | 1,129,171 | 5.59 | 15.53% |
3 Years | 43.14 | 54.4446 | 25.04 | 39.61 | 1,116,372 | -1.55 | -3.59% |
5 Years | 74.04 | 75.14 | 25.04 | 46.19 | 1,083,681 | -32.45 | -43.83% |
Ionis Pharmaceuticals Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). |